Metrics Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma
locally advanced unresectable metastatic urothelial carcinomaerdafitinibenfortumab vedotinindirect treatment comparisonmatching-adjusted indirect comparison
• https://doi.org/10.36469/001c.120954 Pageviews and PDF downloads
Top Countries | |
---|---|
66 | |
37 | |
36 | |
27 | |
23 | |
21 | |
19 | |
12 | |
11 | |
11 |